Neuroscience

#Centessa Pharmaceuticals #Clinical trials #Narcolepsy #Neuroscience #Sleep disorders

Centessa initiates Phase II trial in patients with sleep/wake disorders 

Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.  ORX750 was designed using Nxera Pharma technology to directly… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

New DDW Highlights episode: 11 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

This week in drug discovery (4-8 November) 

News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. The top stories:… Read More

#News

#Dementia #Funding #Investment #Parkinson's #UK Dementia Research Institute

£20m funding offered to advance breakthroughs in dementia research

The UK Dementia Research Institute has received major new government funding to boost translational research into dementia and related neurodegenerative conditions such as Parkinson’s and motor neuron disease. The UK-wide research institute will receive an initial £20 ($25.9) million from the National Institute for Health and… Read More

#News

Neuroscience innovation
#Brain #Comment #Events #Neuroscience #Neuroscience 2024 #Society for Neuroscience

Reflections from SfN’s Neuroscience 2024 

DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having attended a range of presentations, explored the exhibition and engaged with industry attendees, she reflects on the event.   News updates  Whilst Neuroscience 2024 took place, the 2024 Nobel Prizes were announced. For… Read More

#Exclusive Content

Mitochondria
#Mitochondria #Neuroscience #NRG Therapeutics #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. The company says NRG5051 also has potential in other neurological diseases such as amyotrophic lateral sclerosis (ALS). Read More

#Business & Investment #Editor's Choice #News

Tau proteins
#Alzheimer's #Neuroscience #Phase II trial #Tau protein #UCB

Encouraging results for anti-tau antibody presented at CTAD 2024

UCB has reported encouraging Phase IIa data from the TOGETHER (AH0003) study, investigating bepranemab, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease. The results were presented during a late-breaking symposium at the 2024 Clinical Trials… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Collaboration #Parkinson's #SandboxAQ #The Michael J Fox Foundation for Parkinson’s Research (MJFF) #University of Dundee

Partners launch $25m initiative to develop Parkinson’s treatments

SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson's disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) programme. Read More

#Business & Investment #News

The microbiome
#Gut microbiome #Mental health #Microbiome #Psychiatry

Can the gut microbiome unlock new therapeutics in mental health?

Janet Sasso and Rumiana Tenchov, Information Scientists at CAS, discuss the relationship between the gut microbiome and mental health, reporting on topics that CAS has explored over the recent years. The gut-brain axis (GBA), a signalling pathway connecting the gastrointestinal tract and the central nervous system, has increasingly been found… Read More

#Exclusive Content

CT scans of the brain
#Alzheimer's #Clinical trial #Dementia #UK

Accelerator to boost dementia clinical trial participation in UK 

A new initiative hopes to increase the number of people participating in dementia clinical trials in the UK, aiming to identify tens of thousands of potential trial participants.  The new ‘Dementia Trials Accelerator’ initiative hopes to address pharma-identified roadblocks to the delivery of commercial clinical trials in… Read More

#News

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News

Neuroscience innovation
#Drug development #Drug discovery #Neuroscience #Webinar

Watch DDW’s Neuroscience Showcase On Demand

In this free online event at 3pm BST on 24 October, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector.  The showcase includes a panel discussion looking at… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Motor neurone disease #Neurodegenerative disorders #Neuroscience #Nevrargenics

Promising new therapy for ALS progresses to human trials

A new treatment for the most common type of motor neurone disease (MND) could improve the neuronal health of sufferers and allow their nervous systems to improve regeneration. Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a… Read More

#News

Neuron
#Neurology #Neuroscience #Precision medicine #Psychiatry #Webinar

Watch now! DDW Neuroscience Showcase

In this free online event hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel discussion looking at the use of new drug discovery… Read More

#News